Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Kirin to Report PII Results of KW-0761 at ASH
October 25, 2010
- Champix Demand Exceeds Supply Due To Tobacco Tax Increase
October 25, 2010
- Interim Report Presented on Sprycel PMS
October 25, 2010
- Sepracor Renamed Sunovion
October 25, 2010
- 1st-Line Japanese Cohort Analysis Data to Be Presented at ASH
October 25, 2010
- Korosho Requires Novo to Issue Blue Letter on Victoza
October 25, 2010
- Tasigna Effective in 1st-Line in Japanese CML Patients
October 25, 2010
- Korosho to Clarify Criteria for Requiring Safety Information
October 25, 2010
- Daiichi Sankyo, ArQule to Expand Research Collaboration in Oncology
October 25, 2010
- Korosho Proposes Safety Measures for Bisphosphonates
October 25, 2010
- BSI-201 Enters PI in Japan: sanofi-aventis
October 25, 2010
- Chuikyo to Extend Limit on Prescription Term for New Combination Drugs
October 25, 2010
- Lixisenatide Improves Glucose Control in Combination with Basal Insulin
October 25, 2010
- PhRMA to Include Its Demand in US-Japan Talks for Regulatory Reform
October 25, 2010
- NICE Recommends Aricept for Mild AD
October 25, 2010
- Applications for Accreditation of Foreign Manufacturers Simplified
October 25, 2010
- Large Differences in Participation in Multinational Clinical Trials
October 25, 2010
- NDA Review Period Shortening in Japan: Mr Narita
October 25, 2010
- Indacaterol Significantly Improves Breathlessness: Novartis
October 25, 2010
- Korosho Requires Revisions of Package Inserts for Topical Ketoprofen
October 25, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…